Multiple myeloma is the 2nd most common hematological malignancy. Its diagnosis and treatment have changed dramatically in the last decade. Moreover, the disease definition has been updated to allow highly specific biomarkers of end-organ damage. The disease staging system has been revised to combine both measures of tumor burden and disease biology.
Furthermore, therapy has been advanced for the significant improvement in overall response rate and survival. In this video, Dr. Manish Singhal discusses the suspicion and diagnosis of multiple myeloma, new criterions for the diagnosis, basics of treatment, the importance of immunomodulators, choice of drugs and i mprovements in response rate due to the introduction of novel agents.
